Nghiên cứu sự thay đổi nồng độ CA 15-3 huyết tương ở người bệnh ung thư vú được điều trị bằng tamoxifen tại bệnh viện K từ năm 2019 đến 2022=Study on plasma CA 15 - 3 concentration in breast cancer patients treated with tamoxifen at K hospital from 2019 to 2022

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thế Hưng Đặng, Thị Tươi Lê

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Y học cộng đồng, 2024

Mô tả vật lý: tr.198-203

Bộ sưu tập: Metadata

ID: 242072

Thêm vào giỏ

Describe some clinical and paraclinical characteristics and analyze changes in plasma CA 15-3 levels in breast cancer patients treated with Tamoxifen at K Hospital from 2019 to 2022. Research methods: Cross-sectional descriptive study was performed using secondary data on medical records of patients with a confirmed diagnosis of breast cancer, receiving endocrine treatment with Tamoxifen at K Hospital,from 2019 to September2022 and continuous monitoring for at least 6 months.Results:Research results showed that breast cancer patients often have tumors in the most common location, ¼ on the outside, accounting for 43.1%. Tumors may or may not cause pain, and most tumors have firm density (57.7%), unclear borders (60.2%). The ER receptor with positive status was 99.4%, PR receptor with positive status was 91.4%,and both receptors with positive status were 87.2%.CA 15-3 concentration after treatment was lower than that before treatment. CA 15-3 results at 3 time points dispersed around median values of 16.59 U/mL (before treatment), 14.94 U/mL (3 months after treatment) and 14.42 U/mL (6 months after treatment), respectively. The proportion of patients with CA 15-3 levels within normal limits gradually increased over time of treatment(89.6%before treatment
93.8%after 3 months of treatment
95.8% after 6 months, p <
0.05).Conclusion: The cancer marker CA 15-3 combined with clinical and paraclinical characteristics after each treatment cycle plays an important role in supporting to evaluate the effectiveness of breast cancer treatment with Tamoxifen.Mô tả một số đặc điểm lâm sàng, cận lâm sàng và phân tích sự thay đổi nồng độ CA 15-3 huyết tương ở người bệnh ung thư vú được điều trị bằng Tamoxifen tại bệnh viện K từ năm 2019 đến năm 2022. Phương pháp nghiên cứu: Nghiên cứu mô tả sử dụng số liệu hồi cứu trên hồ sơ bệnh án của người bệnh có chẩn đoán xác định ung thư vú, được điều trị nội tiết bằng Tamoxifen tại Bệnh viện K từ năm 2019 đến tháng 9/2022 và theo dõi liên tục ít nhất 6 tháng. Kết quả: Kết quả nghiên cứu cho thấy người bệnh ung thư vú thường xuất hiện khối u ở vị trí phổ biến nhất là 1/4 trên ngoài, chiếm 43,1%. Khối u có thể gây đau hoặc không, đa số khối u có mật độ chắc chiếm 57,7%, ranh giới không rõ chiếm 60,2%. Tình trạng thụ thể nội tiết ER dương tính là 99,4%, PR dương tính là 91,4% và cả hai thụ thể dương tính là 87,2%. Nồng độ CA 15-3 sau điều trị thấp hơn trước điều trị, tại 3 thời điểm nồng độ CA 15-3 phân tán quanh giá trị trung vị lần lượt là 16,59 U/mL (trước điều trị), 14,94 U/mL (sau điều trị 3 tháng) và 14,42 U/mL (sau điều trị 6 tháng). Tỷ lệ người bệnh có nồng độ CA 15-3 trong giới hạn bình thường tăng dần theo thời gian điều trị, trước điều trị có 89,6%, sau điều trị 3 tháng có 93,8% và sau 6 tháng là 95,8% (p <
0,05). Kết luận: Theo dõi sự thay đổi nồng độ CA 15-3 kết hợp với một số dấu hiệu lâm sàng và cận lâm sàng sau mỗi chu kỳ điều trị có vai trò quan trọng giúp đánh giá hiệu quả của phác đồ điều trị bệnh ung thư vú bằng Tamoxifen.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR